Steven Daniel Schwartz is Director at Avalanche Biotechnologies, Inc. (AAVL). They have made 1 open-market trade across 1 company since 2015, most recently 2017-06-12.
CIK 0001615096
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| [AAVL] | SELL · 10b5-1 | 2015-06-15 | 2015-06-17 | $39.86 | $673K | N/A | N/A | N/A |
| [AAVL] | SELL · 10b5-1 | 2015-06-01 | 2015-06-02 | $36.24 | $625K | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-05-22 | 2015-05-22 | $38.38 | $648K | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-05-08 | 2015-05-11 | $33.05 | $570K | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-04-23 | 2015-04-23 | $38.62 | $652K | N/A | N/A | N/A |
| AAVL | SELL · 10b5-1 | 2015-04-09 | 2015-04-13 | $39.73 | $685K | N/A | N/A | N/A |
| AAVL | SELL | 2015-01-13 | 2015-01-15 | $55.46 | $5.0M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.